Pieter Wesseling mainly focuses on Pathology, Glioma, Cancer research, Immunology and Cancer. His specific area of interest is Pathology, where he studies Brain tumor. His work on Diffuse Glioma as part of general Glioma study is frequently linked to Clinical neurology, bridging the gap between disciplines.
Pieter Wesseling interconnects DNA methylation, Primary tumor, DNA repair and Gene expression profiling in the investigation of issues within Cancer research. The study incorporates disciplines such as Platelet and Lung cancer in addition to Cancer. His Temozolomide research incorporates elements of Hazard ratio, Phenotype and Intention-to-treat analysis.
His primary scientific interests are in Pathology, Glioma, Cancer research, Internal medicine and Oncology. His Pathology research focuses on subjects like Melanoma, which are linked to Metastasis. His Glioma research includes themes of DNA methylation and IDH1.
His Cancer research study integrates concerns from other disciplines, such as Mutation, Immunology and Pharmacology. All of his Internal medicine and Cancer and Breast cancer investigations are sub-components of the entire Internal medicine study. Pieter Wesseling combines subjects such as Hazard ratio and Radiation therapy, Temozolomide with his study of Oncology.
Pieter Wesseling mainly investigates Glioma, Cancer research, Pathology, Internal medicine and Oncology. His Glioma research integrates issues from IDH1, Isocitrate dehydrogenase and DNA methylation. His research integrates issues of Cancer, Mutation, Gene, Somatic cell and Platelet in his study of Cancer research.
Pieter Wesseling works mostly in the field of Pathology, limiting it down to concerns involving Magnetic resonance imaging and, occasionally, Positron emission tomography. His study in Internal medicine concentrates on Radiation therapy, Hazard ratio, Temozolomide and Disease. His biological study spans a wide range of topics, including O-6-methylguanine-DNA methyltransferase and Cell growth.
Pieter Wesseling focuses on Glioma, Cancer research, Internal medicine, Oncology and Pathology. Glioma is closely attributed to Ependymoma in his research. He has researched Cancer research in several fields, including Cancer, Platelet, Immunology, IDH1 and Biomarker.
Pieter Wesseling focuses mostly in the field of Internal medicine, narrowing it down to matters related to Epigenetics and, in some cases, MAPK/ERK pathway, PI3K/AKT/mTOR pathway, Tumor suppressor gene and Signal transduction. As part of the same scientific family, Pieter Wesseling usually focuses on Pathology, concentrating on Neuroscience and intersecting with MEDLINE. Pieter Wesseling has included themes like Hazard ratio, Chemotherapy, Performance status and Intention-to-treat analysis in his Radiation therapy study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp;Monika E. Hegi;Warren P. Mason;Martin J. van den Bent.
Lancet Oncology (2009)
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
Genevieve Schindler;David Capper;David Capper;Jochen Meyer;Wibke Janzarik.
Acta Neuropathologica (2011)
DNA methylation-based classification of central nervous system tumours
David Capper;David Capper;David Capper;David T. W. Jones;Martin Sill;Volker Hovestadt.
Diffuse glioma growth: a guerilla war
An Claes;Albert J. Idema;Pieter Wesseling.
Acta Neuropathologica (2007)
International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading
David N. Louis;Arie Perry;Peter Burger;David W. Ellison.
Brain Pathology (2014)
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
Dennis Lindau;Paul Gielen;Michiel Kroesen;Pieter Wesseling;Pieter Wesseling.
Overcoming the blood-brain tumor barrier for effective glioblastoma treatment
O. van Tellingen;B. Yetkin-Arik;M.C. de Gooijer;P. Wesseling;P. Wesseling.
Drug Resistance Updates (2015)
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs
Dominik Sturm;Dominik Sturm;Brent A. Orr;Umut H. Toprak;Volker Hovestadt.
RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics
Myron G. Best;Nik Sol;Irsan Kooi;Jihane Tannous.
Cancer Cell (2015)
Germline mutation of INI1/SMARCB1 in familial schwannomatosis.
Theo J.M. Hulsebos;Astrid S. Plomp;Ruud A. Wolterman;Els C. Robanus-Maandag.
American Journal of Human Genetics (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: